PMGC Holdingsの空売り状況は、投資家がPMGC Holdingsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

PMGC Holdings (NASDAQ:ELAB) 株価情報, 空売り情報

Elevai Labs

PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

PMGC Holdings Inc

American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) shares are trading lower on Tuesday after the company revised its <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">first-quarter financial outlook.</a>
The <a target="_blank" href="https://americanairlines.gcs-web.com/static-files/67f1af16-a067-474b-8127-4cf765e2f202" rel="noreferrer noopener">updated </a>guidance reflects weaker-than-expected revenue, largely due to challenges from Flight 5342 and a downturn in the domestic leisure segment, particularly in March.
The airline now projects its total revenue for the first quarter <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">to be flat compared to the first quarter of 2024.</a>
Previously, the company had expected a 3% to 5% growth in revenue.
The company also anticipates an adjusted loss per diluted share between $0.60 to $0.80, a notable revision from the previous loss forecast range of $0.20 to $0.40. The analyst consensus estimate pegs at a $0.25 loss.
Additionally, American Airlines estimates that Available Seat Miles will remain flat to down 2% year-over-year.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/03/44253100/trump-slaps-50-tariff-on-canadian-steel-aluminum-threatens-auto-industry" rel="noreferrer noopener">Trump Slaps 50% Tariff On Canadian Steel &amp; Aluminum, Threatens Auto Industry</a>
The company's weakened forecast comes amid broader concerns in the airline industry.
Earlier this month, JP Morgan analyst Jamie Baker noted a shift in investor sentiment regarding North American airlines, citing worries over domestic capacity, changing consumer behavior, <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44087114/airlines-face-a-rough-start-to-2025-full-service-carriers-hold-the-advantage-analyst" rel="noreferrer noopener">and reduced government travel.</a>
As a result, share price momentum in 2025 has slowed significantly compared to the rapid gains in late 2024.
Yesterday, Delta Air Lines also downgraded its revenue growth forecast for the March quarter, now expecting a 3% to 4% growth, down <a target="_blank" href="https://www.benzinga.com/general/travel/25/03/44237055/delta-air-lines-cuts-q1-guidance-below-estimates-airline-stocks-fall" rel="noreferrer noopener">from the previous estimate of 7% to 9%.</a>
On a positive note, Southwest Airlines has seen its shares rise, fueled by announcements of initiatives aimed at accelerating EBIT contribution and <a target="_blank" href="https://www.benzinga.com/news/25/03/44245996/why-is-southwest-airlines-stock-rising-today" rel="noreferrer noopener">stock buyback program.</a>
As airlines navigate a period of uncertainty, all eyes are on how the sector adjusts to these new challenges.
Price Action: AAL stock is down 6.8% at $11.65 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44249926/stock-of-the-day-where-will-the-tesla-selloff-end" target="_blank" rel="noreferrer noopener">Stock Of The Day – Where Will The Tesla Selloff End?</a></li>
</ul>
Image via Shutterstock.

Equities

News

Guidance

Markets

Movers

General

What's Going On With American Airlines Stock Today?

TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) hit a technical roadblock, forming <a href="https://www.benzinga.com/topic/death-cross">a Death Cross</a> — a classic bearish signal that suggests trouble ahead.
Despite an eye-popping 102% revenue surge, the stock has been in a free fall, shedding over 43% year to date and 35% in the past month alone.
Investors are now left wondering: is this a moment of capitulation, or could WULF stock stage a surprise rebound?
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="632" height="485" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11125622/Screenshot-2025-03-11-at-8.28.10-PM.png" alt="" class="wp-image-819251" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11125622/Screenshot-2025-03-11-at-8.28.10-PM.png 632w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11125622/Screenshot-2025-03-11-at-8.28.10-PM-300x230.png 300w" sizes="(max-width: 632px) 100vw, 632px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h1 class="wp-block-heading">Death Cross Spells Trouble</h1>
The Death Cross occurs when a stock's 50-day simple moving average dips below its 200-day simple moving average, often viewed as a strong bearish indicator. Supporting this grim picture, TeraWulf stock at $3.04 sits well below key moving averages: the eight-day at $3.51, the 20-day at $4.02, the 50-day at $4.93 and the 200-day at $5.07.
With these levels acting as resistance, TeraWulf stock remains in a downtrend.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44232722/will-bitcoin-test-69000-watch-this-date-for-the-end-of-the-window-of-weakness">Will Bitcoin Test $69,000? Watch This Date For The End Of The &#8216;Window of Weakness&#8217;</a>
<h1 class="wp-block-heading">Bearish Trend, But Signs Of Accumulation?</h1>
While the short-term trend remains strongly bearish, some traders might find a glimmer of hope. Buying pressure has started to emerge, which could indicate a potential shift in sentiment if momentum builds. 
The Moving Average Convergence Divergence (MACD) indicator sits at a negative 0.53, reinforcing the bearish stance, while the Relative Strength Index (RSI) of 33.30 suggests TeraWulf stock is approaching oversold territory.
<h1 class="wp-block-heading">Fundamentals vs. Technicals: Who Wins?</h1>
Despite the technical weakness, TeraWulf's fundamentals paint a different picture. The company <a href="https://www.tipranks.com/news/terawulf-inc-wulf-shares-dropping-despite-impressive-revenue-leap">posted</a> a massive 102% revenue increase to $140.1 million, fueled by strong Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining output and a lucrative 10-year data center lease with Core42.
But, operational costs remain a concern and the market reaction has been harsh.
If sentiment shifts, a rebound could be in the cards — but for now, the Death Cross is the dominant force.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44221339/why-did-trumps-strategic-crypto-reserve-not-include-xrp">Why Did Trump&#8217;s Strategic Crypto Reserve Not Include XRP?</a></li>
</ul>
Photo: Parilov on Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Technicals

Trading Ideas

$BTC

WULF

TeraWulf Stock Tanks: Death Cross Spells Trouble For Bitcoin Miner

Macro Economic Events

Politics

Global

Economics

Canada Pm Designate Carney Says My Government Will Keep Tariffs Until Americans Show Us Respect And Make Credible, Reliable Commitments To Free And Fair Trade

Donald Trump made this a centerpiece of his campaign for a second term, suggesting that he could get oil and gas producers to turn on the spigots and drive the prices of gasoline below $2.
Judging by last week&#8217;s address to Congress, it is not an idea the President seems likely to drop.
A lot of oil and gas executives wish he would.
&#8220;Drill, Baby, Drill&#8221; and cheap gas is a cool campaign theme. It is a disaster for profit margins at small to midsize oil and gas producers.
Sustained high levels of production would destroy many of these companies.
The industry has been down this road before and has no desire to go there again.
As Pioneer Natural Resources CEO Scott Sheffield said last year when the topic first arose at a campaign rally, &#8220;No company wants to risk another price collapse. We are disciplined now because we&#8217;ve learned from past cycles.&#8221;
The big companies are not fans of the idea either. During the period between the election and inauguration, the President of Exxon&#8217;s (Ticker: XOM) upstream division, Liam Mallon, told Bloomberg, &#8220;I think a radical change is unlikely because the vast majority, if not everybody, is primarily focused on the economics of what they&#8217;re doing.&#8221;
He added, &#8220;I don&#8217;t think we&#8217;re going to see anybody in the drill, baby, drill mode. I really don&#8217;t.&#8221;
While the industry may resist, it is safe to say the President is going to push the point.
What &#8220;Drill, Baby, Drill&#8221; is likely to accomplish is touching off a wave of oil patch merger and acquisition activity.
If we do begin to see large production increases coupled with a slowdown in economic activity because of policy decisions, smaller companies are going to struggle.
Just as we saw in the banking industry over the past 30 years, scale and size are going to be primary determinants of profits.
The bigger you are, the more likely you will be to stay profitable in the era of &#8220;Drill, Baby, Drill.&#8221;
The smart play is going to be for smaller companies to look for a larger partner.
The smarter play is to look for companies that are attractive targets that would be good buys to add attractive assets and gain scale but are capable of growing on a standalone basis.
Epsilon Energy (Ticker: EPSN) is a perfect example of a smaller energy company that will allow investors to have the best of both worlds.
Epsilon Energy Ltd. is a debt-free independent energy company focused on natural gas and oil production, with core assets in the Northeast Pennsylvania Marcellus Shale, the Permian Basin, and Alberta, Canada. The company maintains a strong balance sheet with $8.8 million in cash and $45 million in undrawn revolver capacity, providing financial flexibility for growth and shareholder returns. With stable midstream revenues, low-cost natural gas production, and high-margin oil upside in the Permian and Alberta, EPSN presents a balanced mix of stability and growth potential.
EPSN has a core position in the Marcellus, one of the lowest-cost natural gas basins in the U.S. The company holds 5,142 net acres with 139 producing wells and a 35% stake in the Auburn Gas Gathering System, which provides stable midstream revenues.
The company also has 400,000-500,000 ft. of undeveloped inventory they can bring online as natural gas prices improve.
A relaxation of regulations that allows for new pipeline capacity to be added in the region would be an enormous plus for Epsilon.
Epsilon&#8217;s expansion into the Permian Basin is a game-changer. The company has poured $38 million into its Ector County, TX position, shifting its production mix toward high-margin oil. It&#8217;s already seeing strong results, with seven producing wells and a massive runway of 30-40 future drilling locations.
More importantly, this move diversifies EPSN away from natural gas price volatility. Natural gas has been a rough ride lately, but oil demand remains resilient. If prices remain steady, Epsilon&#8217;s forecasted 140%+ growth in liquids production could drive significant cash flow expansion.
Epsilon has maintained a disciplined approach to capital allocation, balancing strategic growth investments with consistent shareholder returns.
A significant portion of cash flow was directed toward the Permian Basin, where it is aggressively expanding its oil-weighted production.
20% was allocated to its core Marcellus asset, supporting ongoing development in one of the lowest-cost natural gas basins in the country.
The company also invested $2.6 million in its newly formed Alberta joint venture, a move designed to open long-term growth opportunities in a promising Canadian oil and gas play.
Beyond growth initiatives, EPSN has remained committed to returning capital to shareholders. The company paid out $5.5 million in dividends.
$2.2 million was allocated to stock buybacks, increasing the value of remaining shares.
In March 2024, EPSN authorized a new buyback program for up to 2.2 million shares, demonstrating continued confidence in its own undervalued stock.
Since mid-2022, it has already repurchased 1.82 million shares at an average price of $5.24 per share, signaling a strong commitment to enhancing shareholder value.
The combination of attractive assets in two of the more attractive producing regions in the country could prove to be an enticing target for a potential buyer.
At the same time, management has positioned the company to grow and made smart investments to increase scale organically.
Either way, Epsilon Energy allows investors to &#8220;Win, Baby, Win&#8221; no matter how &#8220;Drill, Baby, Drill&#8221; plays out.

Opinion

EPSN

Under the Radar: The Real Impact of Increased Drilling on Oil Market Dynamics

Investors with a lot of money to spend have taken a bullish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 9 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 11%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $351,574, and 3 are calls, for a total amount of $404,070.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $95.0 for DexCom over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 302.88, with a total volume reaching 1,003.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $65.0 to $95.0, throughout the last 30 days.
<h3>DexCom Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741713344_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$5.8</td>
<td>$5.3</td>
<td>$5.68</td>
<td>$95.00</td>
<td>$227.2K</td>
<td align="right">27</td>
<td align="right">400</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.9</td>
<td>$15.6</td>
<td>$15.6</td>
<td>$80.00</td>
<td>$138.8K</td>
<td align="right">537</td>
<td align="right">0</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$11.5</td>
<td>$11.1</td>
<td>$11.5</td>
<td>$80.00</td>
<td>$118.4K</td>
<td align="right">11</td>
<td align="right">103</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$8.5</td>
<td>$8.2</td>
<td>$8.3</td>
<td>$65.00</td>
<td>$62.2K</td>
<td align="right">660</td>
<td align="right">75</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$13.3</td>
<td>$12.7</td>
<td>$12.7</td>
<td>$85.00</td>
<td>$58.4K</td>
<td align="right">6</td>
<td align="right">46</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Where Is DexCom Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,398,420, the DXCM's price is down by -1.84%, now at $69.42. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
<h3>Professional Analyst Ratings for DexCom</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $96.33.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for DexCom, targeting a price of $104. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on DexCom, which currently sits at a price target of $82. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for DexCom, targeting a price of $103. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for DexCom, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

DXCM

DexCom Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bearish stance on Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HPE, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Hewlett Packard.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 62%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $28,380, and 7, calls, for a total amount of $281,247.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $17.0 for Hewlett Packard during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Hewlett Packard stands at 632.75, with a total volume reaching 9,497.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Hewlett Packard, situated within the strike price corridor from $10.0 to $17.0, throughout the last 30 days.
<h3>Hewlett Packard Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741713339_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.3</td>
<td>$1.25</td>
<td>$1.29</td>
<td>$17.00</td>
<td>$65.9K</td>
<td>210</td>
<td>2.1K</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.46</td>
<td>$2.42</td>
<td>$2.42</td>
<td>$15.00</td>
<td>$58.0K</td>
<td>1.7K</td>
<td>33</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$1.36</td>
<td>$1.27</td>
<td>$1.28</td>
<td>$17.00</td>
<td>$46.8K</td>
<td>210</td>
<td>861</td>
</tr>
<tr>
<td>HPE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$6.15</td>
<td>$6.0</td>
<td>$6.07</td>
<td>$10.00</td>
<td>$30.3K</td>
<td>185</td>
<td>50</td>
</tr>
<tr>
<td>HPE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$1.78</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$15.00</td>
<td>$28.3K</td>
<td>415</td>
<td>206</td>
</tr>
</tbody>
</table>

<h3>About Hewlett Packard</h3>
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure. It uses a primarily outsourced manufacturing model and employs 60,000 people worldwide.
Following our analysis of the options activities associated with Hewlett Packard, we pivot to a closer look at the company's own performance.
<h3>Current Position of Hewlett Packard</h3>
<ul>
<li>Currently trading with a volume of 10,310,268, the HPE's price is up by 2.12%, now at $15.4. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 84 days.</li>
</ul>
<h3>Professional Analyst Ratings for Hewlett Packard</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $19.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Hewlett Packard, targeting a price of $24. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Hewlett Packard with a target price of $20. 
&#x2A; An analyst from Loop Capital persists with their Hold rating on Hewlett Packard, maintaining a target price of $16. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Hewlett Packard, maintaining a target price of $20. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Hewlett Packard, maintaining a target price of $17. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hewlett Packard options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Spotlight on Hewlett Packard: Analyzing the Surge in Options Activity

Investors with significant funds have taken a bullish position in Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in ILMN usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 62% being bullish and 25% bearish. Of all the options we discovered, 7 are puts, valued at $381,330, and there was a single call, worth $116,000.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $135.0 for Illumina over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Illumina's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Illumina's whale activity within a strike price range from $85.0 to $135.0 in the last 30 days. 
<h3>Illumina Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741713333_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/25/25</td>
<td>$25.0</td>
<td>$21.8</td>
<td>$23.4</td>
<td>$110.00</td>
<td>$163.8K</td>
<td align="right">0</td>
<td align="right">70</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.1</td>
<td>$9.8</td>
<td>$11.6</td>
<td>$100.00</td>
<td>$116.0K</td>
<td align="right">136</td>
<td align="right">108</td>
</tr>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$49.5</td>
<td>$47.1</td>
<td>$49.5</td>
<td>$135.00</td>
<td>$59.4K</td>
<td align="right">12</td>
<td align="right">12</td>
</tr>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$2.5</td>
<td>$2.35</td>
<td>$2.5</td>
<td>$85.00</td>
<td>$39.5K</td>
<td align="right">694</td>
<td align="right">190</td>
</tr>
<tr>
<td>ILMN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.3</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$95.00</td>
<td>$34.3K</td>
<td align="right">519</td>
<td align="right">151</td>
</tr>
</tbody>
</table>

<h3>About Illumina</h3>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Illumina Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,177,576, the price of ILMN is up by 2.93%, reaching $88.48.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 51 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Illumina</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $130.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays downgraded its action to Underweight with a price target of $100. 
&#x2A; An analyst from Canaccord Genuity persists with their Hold rating on Illumina, maintaining a target price of $115. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Illumina, maintaining a target price of $190. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Illumina, targeting a price of $90. 
&#x2A; In a cautious move, an analyst from Stephens &amp; Co. downgraded its rating to Overweight, setting a price target of $156. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Illumina, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

ILMN

Illumina Unusual Options Activity

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/03/2025-03-11_08h44_04.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Take Partial Profits On Hedges</h4>
After the sell off, consider taking partial profits on hedges. 
<h4 class="wp-block-heading">Nibbling</h4>
Aggressive investors may consider nibbling stocks and ETFs that are entering buy zones.&nbsp; Nibbling simply means entering very, very small tranches in existing recommendations.
As a caution, be sure to not gorge.&nbsp;&nbsp;
<h4 class="wp-block-heading">Stock Market Put</h4>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-hedges-trump-stock-market-put-spy-mc-03112025">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>The chart shows the stock market fell to the bottom band of support zone 1.</li>
<li>When the stock market approaches the bottom band of a support zone, a bounce is expected.&nbsp; This is exactly what happened yesterday afternoon.</li>
<li>On March 4, we wrote: </li>
</ul>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">Unless President Trump changes his mind or the Fed changes its policy, the stock market going to the support zone is the highest probability scenario at this time.
</blockquote>
<ul>
<li>In the short term, here are the key points:
<ul>
<li>Selling yesterday was exaggerated by margin calls to momo crowd accounts.</li>
<li>At the end of the day, the stock market rallied as short sellers bought to cover on the stock market approaching the low band of the support zone.</li>
<li>In the evening, futures took another leg down on expectations of a selloff in Asia.</li>
<li>Markets stabilized in Asia.&nbsp; Chinese stocks even gained.&nbsp; Action in Asia brought in buying in the futures in the U.S.</li>
</ul>
</li>
<li>RSI on the chart shows the stock market is oversold.&nbsp; Oversold markets tend to bounce.</li>
<li>The chart shows the selloff yesterday was on higher volume.&nbsp; This indicates that there was mild conviction in the selloff.&nbsp; The volume needed to be higher than it was to wash out the sellers – this indicates a high probability of another leg down.&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>The chart shows the stock market is below the 200 day moving average.&nbsp; We previously shared with you:</li>
</ul>
<ul>
<li>The 200 day moving average is very powerful, and all investors should pay attention to it.</li>
<li>The reason the 200 day moving average is so powerful is because legions of investors believe in it and act on it, and the media publicizes it.</li>
<li>Other than the deeply held myth, the 200 day moving average does not have any special power.&nbsp; Afterall, why not a 190 day or 210 day moving average?</li>
<li>Rigorous analysis shows that the 200 day average by itself has no magical power.</li>
<li>Legions of investors buy stocks when the stock market pulls back to the 200 day moving average because they erroneously consider the 200 day moving average as a major support.&nbsp; There is no analytically valid basis for this myth.</li>
<li>Legions of investors also sell stocks when the stock market breaks below the 200 day moving average.&nbsp; Again, there is no analytical basis for this belief.</li>
<li>Below are extremely important points for prudent investors to fully grasp. 
<ul>
<li>During President Trump's first term, the stock market had a Trump put.&nbsp; In plain English, a Trump put meant that Trump did not allow a significant drop in the stock market.</li>
<li>Every time the stock market started to drop during his first term, Trump jumped into action.  For example, in December 2018, when the stock market started falling on the Fed raising interest rates, Trump relentlessly berated Fed Chair Powell.  Ultimately, Powell reversed course.  Powell's reversal caused the stock market to start a mega party. In the process, Powell sowed the seeds of inflation.</li>
<li>When Trump was re-elected, it was natural for investors to believe that once again the stock market had a Trump put.&nbsp; Prudent investors need to remember that investors suffer from recency bias. &nbsp; In plain English, recency bias means that most often, investors believe that the road ahead will be the same as the road behind.</li>
<li>This time, Trump has experience from his first term.&nbsp; Instead of claiming the glory of the stock market going up during his presidency, Trump appears to have a bigger fish to fry.&nbsp; The bigger fish is to truly make America great again.</li>
<li>An easy way for prudent investors to understand what Trump appears to be wanting to do is to think of investors in the U.S. as addicts who have been continuously fed intoxicating substances by the U.S. government over the last 20 years.  With borrowing and spending, it got so bad that no one would even talk about detox.  Whether you like Trump or dislike Trump, the fact is that he is the first president since Ronald Reagan who appears to have the guts to take the country through a detox.  Here is the key question for investors – will Trump carry through a full detox, or will he get distracted along the way?</li>
</ul>
</li>
<li>In the long run, detox is good for the country and for investors.&nbsp; In the short run, detox may upset the apple cart.</li>
<li>No one can deny that the U.S. government cannot continue with the following:
<ul>
<li>Massive borrowing and spending</li>
<li>Growing the national debt to unsustainable levels</li>
<li>Transferring massive wealth from the U.S. to other countries such as China</li>
<li>Paying for highly inefficient and bloated bureaucracy as well as massive frauds</li>
<li>Paying for the defense of Europe</li>
</ul>
</li>
<li>The JOLTS report was released at 10am ET.</li>
<li>Consumer Price Index (CPI) is ahead on Wednesday at 8:30am ET, and Producer Price Index (PPI) will be released on Thursday at 8:30am ET.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Tesla Inc (TSLA).
In the early trade, money flows are neutral in Amazon.com, Inc. (AMZN), NVIDIA Corp (NVDA), Microsoft Corp (MSFT), and Meta Platforms Inc (META).
In the early trade, money flows are negative in Alphabet Inc Class C (GOOG) and Apple Inc (AAPL).
In the early trade, money flows are like a yoyo in S&amp;P 500 ETF (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  The proprietary protection band from The Arora Report puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Hedges Become Profitable, Trump Stock Market Put Failed – Trump Has Bigger Fish To Fry

J.P. Morgan analyst Rahul Krotthapalli reiterated a <a target="_blank" href="https://www.benzinga.com/quote/WEN/analyst-ratings" rel="noreferrer noopener">Neutral rating</a> on the shares of Wendy&#8217;s Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a price target of $17.00.
Wendy&#8217;s first in-person investor update since 2019 featured CEO Kirk Tanner reflecting on his first year and outlining a strategy for the brand&#8217;s turnaround.
With 7,240 units and under $15 billion in global sales, Wendy&#8217;s lags behind competitors like McDonald&#8217;s Corp, KFC, and others, said the analyst.
The company has a less developed international presence, with around 82% of units and 87% of sales in the U.S. This, coupled with a sub-1x sales/investment ratio, has hindered growth.
Wendy&#8217;s international markets, excluding Canada, have struggled to sustain the necessary investments for scaling.
The total free cash flow (FCF) generation for the next four years, accounting for the full capital intensity of the business, is expected to be over $650 million, compared to a comparable outlook of around $700-800 million or the company&#8217;s CFO estimate of $1.1-1.2 billion based on base capital expenditure definitions.
The analyst would have appreciated a more thorough discussion on improving the sales/investment ratio and unit economics, as well as a deeper focus on the crucial role of technology and talent in Wendy&#8217;s brand turnaround.
The focus was on boosting the equity story by revitalizing the business and brand momentum through various topline and operational initiatives.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44246040/kohls-anticipates-sales-and-profit-dip-in-2025-slashes-dividend-by-75-stock-tanks" rel="noreferrer noopener">Kohl&#8217;s Anticipates Sales And Profit Dip In 2025, Slashes Dividend By 75%, Stock Tanks</a>
According to the analyst, Technology is becoming more standardized, while talent is still scarce in the industry, which is quickly adapting to upskill and enhance all areas of the business using AI.
Attracting and retaining highly skilled engineers and data scientists is challenging, especially when competing with QSR peers with much larger global sales.
Around $150 million in capital expenditure over the next four years is allocated to scaling digital capabilities and modernizing the tech stack to restart growth.
This is also supported by a significant increase in general and administrative (G&amp;A) investments, including a ~$25 million increase in F25, with limited near-term leverage, per the analyst.
The analyst highlighted that investments are being made to speed up the deployment of digital menu boards (currently in ~300 stores), Voice AI-enabled drive-thrus (in ~100 stores), and digital kiosks (handling ~75% of in-store dining transactions).
A new performance matrix is being implemented across the U.S. system, focusing on customer visits/frequency, customer satisfaction, operations, people, and financial excellence, with increased oversight on franchise accountability.
Customer segmentation is driving menu innovation, with new lemonade flavors and formats planned for this summer, targeting the Hispanic (23% of QSR traffic) and Gen Z (21%) cohorts.
The analyst further noted that Families (35% of QSR traffic) are another area of focus as Wendy&#8217;s has lost share in the past few years, which will be a focus area.
Canada leads the international segment, accounting for over 45% of its sales and about 35% of its units. The international business currently represents around 13% of system sales and 18% of units, with plans to grow at an 11% unit CAGR, reaching approximately 2,000 locations (24% of system units) by 2028.
The update lacked a deeper discussion on improving the sales/investment ratio and technology and talent investments, which are crucial for the brand&#8217;s future success and confidence in its growth plans, similar to its modest 3-4% global unit growth target, noted the analyst.
Price Action: WEN shares traded lower by 2.54% at $15.19 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44245996/why-is-southwest-airlines-stock-rising-today" target="_blank" rel="noreferrer noopener">Why Is Southwest Airlines Stock Rising Today?</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Price Target

Reiteration

Analyst Ratings

Analyst Sees Wendy's Playing Catch-Up, Needs Stronger Focus on Tech, Talent & Global Expansion

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) with a Buy and maintains $30 price target.

OLMA

HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and maintains $17 price target.

Core Scientific, Inc. - Class A Common Stock

CORZ

HC Wainwright & Co. Reiterates Buy on Core Scientific, Maintains $17 Price Target

BitMEX co-founder Arthur Hayes remains unfazed by Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent correction, viewing it as part of a natural cycle in a bull market. He believes macroeconomic forces will determine the <a href="https://www.benzinga.com/money/bitcoin-price-prediction">next major move</a>.  
What Happened: In a <a href="https://x.com/CryptoHayes/status/1899261481805566368">post</a> on X on Tueday, Hayes urges investors to stay patient, expecting Bitcoin to find support around $70,000—a standard 36% retracement from its $110,000 all-time high. 
He predicts a major stock market crash and the failure of a key financial institution before central banks step in with liquidity easing.
For traders, he suggests the safest move is waiting for central bank action to avoid prolonged drawdowns, though aggressive buyers may front-run the pivot.
In a separate <a href="https://x.com/CryptoHayes/status/1899293947064942874">post</a>, Hayes reiterated that Bitcoin operates as a true free market, trading 24/7 without bailouts—liquidations happen naturally. 
Stocks, by contrast, trade only on weekdays, are restricted to certain participants, and often receive government intervention when politically convenient. 
In a fiat liquidity crisis, Hayes asserts, Bitcoin moves first—both down and up—before equities follow.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44244951/bitcoins-heading-to-73000-without-a-fresh-narrative-10x-research">Bitcoin&#8217;s Heading To $73,000 Without A Fresh Narrative: 10x Research</a>
What's Next: Hayes further acknowledged Bitcoin's rough start to the week, projecting a move to $78,000. 
If Bitcoin struggles, he sees $75,000 as the next key level. He warns of potential volatility due to significant open interest in options between $70,000-$75,000.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">An ugly start to the week. Looks like <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> will retest $78k. If it fails, $75k is next in the crosshairs. There are a lot of options OI struck $70-$75k, if we get into that range it will be violent. <a href="https://t.co/q4cq0rthGJ">pic.twitter.com/q4cq0rthGJ</a>
&mdash; Arthur Hayes (@CryptoHayes) <a href="https://twitter.com/CryptoHayes/status/1898867933679616103?ref_src=twsrc%5Etfw">March 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44250990/bitcoin-down-17-in-30-days-how-much-lower-can-it-go">Bitcoin Down 17% In 30 Days: How Much Lower Can It Go?</a></li>
</ul>
Image: Shutterstock

Arthur Hayes: 'Be Patient' — Bitcoin's 36% Correction Is Just Another Bull Market Move

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) with a Buy and maintains $16 price target.

ATXS

HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Buy and maintains $40 price target.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

HC Wainwright & Co. Reiterates Buy on Jasper Therapeutics, Maintains $40 Price Target

Management

Bank Of America Has Eliminated Roles For 150 Junior Bankers In Its Investment Bank; Will Offer Most Bankers Roles In Other Businesses; Job Cuts Are Part Of Annual Cull; Also Cut More Than 10 Managing Directors In Investment Banking, Global Markets Weeks Earlier

HC Wainwright &amp; Co. analyst Ed Arce reiterates Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) with a Buy and maintains $32 price target.

SGMT

HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target

COWZ

IBKR

NFLX

VRTX

CNBC Halftime Report Final Trades: Netflix, Meta Platforms, Vertex Pharmaceuticals, Interactive Brokers Group, Pacer US Cash Cows 100 ETF

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and raises the price target from $65 to $70.

Needham Maintains Buy on WNS (Hldgs), Raises Price Target to $70

In the current session, Infosys Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFY#NYSE">INFY</a>) is trading at $19.11, after a 1.70% decrease. Over the past month, the stock decreased by 13.91%, and in the past year, by 2.45%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1741712439_0.png" alt="Past Year Chart" />

<h3>Infosys P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 110.17 in the IT Services industry, Infosys Inc. has a lower P/E ratio of 24.61. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1741712439_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

INFY

Price Over Earnings Overview: Infosys

UBER

Live On CNBC, Steve Weiss Announces Sold Dick's Sporting Goods; Vertiv; Uber Technologies

Press Releases

PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors

Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB)

Health Care

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists

PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market

PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

ELAB

AXIL Brands

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

PMGC Holdings

Flora Growth

Mannatech

Natural Alternatives International, Inc. - Common Stock

Natural Alternatives Intl

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Enter

Safety Shot

Shineco

Synergy CHC

United-Guardian

Upexi

Eon Labs

Screenshot 2024-05-25 at 12.27.19 AM

Biotech

Interview

Ozempic And Wegovy Can Lead To Major Muscle Loss – This Company May Have A Solution

Screenshot 2024-05-16 at 5.52.00 PM

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Comments

PMGC Holdings

空売り

PMGC Holdings (NASDAQ:ELAB) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル